NRG1 and non-small cell lung carcinoma: The clinical trial NCT03805841 [70] evaluated the ORR to tarloxotinib in NSCLC patients harboring insertion in exon 20 of the EGFR gene, activating mutation of HER2 or NRG1 fusion.